Vaxtracker: Active on-line surveillance for adverse events following inactivated influenza vaccine in children

Vaccine

Volumn 32, Issue 42, 2014, Pages 5503-5508

  Cashman, Patrick ^a   Moberley, Sarah ^a   Dalton, Craig ^a   Stephenson, Jody ^a   Elvidge, Elissa ^a   Butler, Michelle ^a   Durrheim, David N ^a,b  

^a HUNTER NEW ENGLAND POPULATION HEALTH   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Active surveillance; Adverse Events Following Immunisation (AEFI); Influenza vaccine; Online survey; Post marketing surveillance; Vaccine safety

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE;

ARTHRALGIA; ARTICLE; AUSTRALIA; CHILD; DRUG SAFETY; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEALTH SURVEY; HUMAN; INFLUENZA; INJECTION SITE REACTION; LYMPHADENOPATHY; MYALGIA; ONLINE SYSTEM; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SEIZURE; VACCINATION; VACCINATION REACTION; WEAKNESS; DRUG SURVEILLANCE PROGRAM; E-MAIL; FEMALE; INTERNET; MALE; MOBILE PHONE; PRESCHOOL CHILD; PROCEDURES; TEXT MESSAGING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CELL PHONES; CHILD; CHILD, PRESCHOOL; ELECTRONIC MAIL; FEMALE; HUMANS; INFLUENZA VACCINES; INTERNET; MALE; NEW SOUTH WALES; POPULATION SURVEILLANCE; PRODUCT SURVEILLANCE, POSTMARKETING; TEXT MESSAGING;

EID: 84922401673     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.061     Document Type: Article

References (12)

1. European Medicines Agency Explanatory note on the withdrawal of the note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96) and of the core SmPC/PL for inactivated seasonal influenza vaccines 2013, EMA/CHMP/VWP/232674/2013.
2. Australian Technical Advisory Group on Immunisation The Australian immunisation handbook 2013, National Health and Medical Research Council, Canberra. 10th ed.
3. Armstrong P.K., Dowse G.K., Effler P.V., Carcione D., Blyth C.C., Richmond P.C., et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011, 1:e000016. 10.1136/bmjopen-2010-000016ent.
4. Joint Australian Technical Advisory Group on Immunisation (ATAGI) and Therapeutic Goods Administration (TGA) Seasonal Influenza Vaccine Safety Ad Hoc Working Group Review of data on the safety of seasonal influenza vaccines, particularly Fluvax (CSL Biotherapies)in adults and children >10 years 2012.
5. Stokes B. Ministerial review into the public health response into the adverse events to the seasonal influenza vaccine 2010, Department of Health, Government of Western Australia.
6. Horvath J. Review of the management of adverse events associated with Panvax and Fluvax 2011, Commonwealth of Australia.
7. Dalton C.B., Carlson S.J., Butler M.T., Elvidge E., Durrheim D.N. Building influenza surveillance pyramids in near real time, Australia. Emerg Infect Dis [Internet] 2013, (November (11)). 10.3201/eid1911.121878.
8. Patel M.M., Haber P., Baggs J., Zuber P., Bines J.E., Parashar U.D. Intussusception and rotavirus vaccination: a review of the available evidence. Expert Rev Vaccines 2009, 8(November (11)):1555-1564.
9. Global Advisory Committee on Vaccine Safety (GACVS), WHO secretariat Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS. Expert Rev Vaccines 2009, 8(June (6)):705-716.
10. Banerjee A.K., Okun S., Edwards I.R., Wicks P., Smith M., Mayall S., et al. Patient-Reported Outcome Measures in Safety Event Reporting - PROSPER Consortium Guidance. Drug Saf 2013, 36:1129-1149.
11. Mehta U., Milstien J.B., Duclos P., Folb P.I. Developing a national system for dealing with adverse events following immunization. Bull World Health Organ 2000, 78(2):170-177.
12. Petousis-Harris H., Poole T., Turner N., Reyonds G.I. Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: the importance of routine active safety surveillance. Vaccine 2012, 30(33):4945-4952.